PDCD1 and cancer: Given the inhibitory impact of the PD-1/PD-L1 axis on T cell activation and the antitumor response, checkpoint blockade therapy involving anti-PD-1 and anti-PD-L1 antibodies has found widespread application in the treatment of various cancers, especially solid tumors [39].